Maxim Group Initiates Coverage on Talphera (NASDAQ:TLPH)

Equities research analysts at Maxim Group initiated coverage on shares of Talphera (NASDAQ:TLPH) in a report issued on Monday, Benzinga reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 202.69% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Talphera in a report on Thursday, March 7th.

Talphera Stock Performance

Shares of NASDAQ TLPH opened at $0.99 on Monday. Talphera has a 1 year low of $0.43 and a 1 year high of $1.61. The company’s 50-day simple moving average is $1.10. The stock has a market cap of $16.84 million, a PE ratio of -0.67 and a beta of 0.46.

Talphera (NASDAQ:TLPH) last released its earnings results on Wednesday, March 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $0.28 million for the quarter. On average, research analysts anticipate that Talphera will post -1.12 earnings per share for the current year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.